re.Mind Capital Ltd.
re.Mind Capital Ltd. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at re.Mind Capital Ltd..
re.Mind Capital Ltd. is a company.
Key people at re.Mind Capital Ltd..
Key people at re.Mind Capital Ltd..
re.Mind Capital Ltd. is a venture capital firm specializing in early-stage investments in mental health, brain health, and human flourishing, with a focus on innovative areas like new pharma, novel modalities, brain-computer interfaces, and digital health.[1][4] Founded by serial entrepreneur Christian Angermayer alongside partners Jan Hardorp and Max de Vere, it operates as the mental health VC arm of Angermayer's Apeiron Investment Group, targeting minority stakes from Series A to pre-IPO stages.[1][2][3] The firm's mission centers on advancing breakthroughs in neurological and mental health technologies, backed by a track record of 15 investments, including recent deals in neurotech companies like Blackrock Neurotech and Motif Neurotech.[3] Its impact on the startup ecosystem lies in providing not just capital but strategic board seats and operating support to scale transformative health innovations.[3]
re.Mind Capital was established by Christian Angermayer, a prominent serial entrepreneur and investor, in partnership with Jan Hardorp and Max de Vere, as a dedicated venture arm under the Apeiron Investment Group family office.[1][2][3] While the exact founding year is not specified in available sources, the firm's activity traces back to at least 2021, evidenced by its lead investment in Ksana Health's $2M seed round for a mental health monitoring platform.[3] This early deal highlighted its evolution toward specialized focus: from broad health tech to pioneering mental and neurological advancements, including brain-computer interfaces, reflecting Angermayer's vision for objective, tech-driven mental health solutions akin to a "Fitbit for the mind."[3]
re.Mind Capital rides the surging wave of neurotechnology and mental health innovation, fueled by post-pandemic demand for scalable, objective brain health solutions amid rising neurological disorders.[1][3][4] Timing is ideal as brain-computer interfaces (e.g., Blackrock Neurotech) and digital monitoring platforms (e.g., Ksana Health) converge with AI and wearables, addressing gaps in traditional pharma.[3] Market forces like insurer adoption (Ksana's major backer) and venture momentum in neurotech ($41M Precision round) amplify its position.[3] The firm influences the ecosystem by funding pioneers, bridging family office resources with startup scaling, and normalizing mental health as a tech frontier—potentially accelerating human flourishing tech adoption.[4]
re.Mind Capital is poised to deepen its dominance in neurotech, with likely expansions into AI-driven brain interfaces and personalized pharma as Series A-to-IPO pipelines mature.[3] Trends like regulatory tailwinds for digital therapeutics and multimodal neuro-data integration will shape its trajectory, amplifying returns from exits in high-growth portfolios.[3] Its influence may evolve from niche investor to ecosystem shaper, drawing more LPs to mental health VC and humanizing tech's role in well-being—echoing its founding vision of redefining health through relentless innovation.[1][4]
